BNP Paribas Asset Management
CTKB icon

BNP Paribas Asset Management’s Cytek Biosciences CTKB Stock Holding History

BNP Paribas Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,856
Closed -$6K – 1917
2025
Q2 		$6K Buy
+1,856
New +$6.18K ﹤0.01% 1919

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Asset Management's CTKB Position: Q3 2025 in Review

BNP Paribas Asset Management sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 1,856 shares — an estimated $6K sold.

BNP Paribas Asset Management first reported a position in CTKB in Q2 2025 and held it in 1 quarter. The position peaked at $6K in Q2 2025. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • BNP Paribas Asset Management reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Asset Management sold 1,856 Cytek Biosciences shares in Q3 2025, an estimated $6K.
  • BNP Paribas Asset Management first reported a position in Cytek Biosciences in Q2 2025 and held it in 1 quarter.
  • BNP Paribas Asset Management's Cytek Biosciences position peaked at $6K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on BNP Paribas Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.